Bryant Furlow

Personalized medicine is changing oncology nursing. This primer explains best practices for collecting and preparing biospecimens used to guide therapy.

Psychosocial decline occurs in an estimated one-third of patients undergoing radiotherapy for cancer. These declines may sometimes be ameliorated by vigilant recognition of the need to refer patients for psychosocial support interventions.

High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.

Some patients undergoing radiotherapy for cancers of the head, neck, and brain are at risk for endocrinopathies. This article reviews the risks, detection, and management of radiotherapy-induced hypopituitarism.

Recent studies show the evidence continues to support exercise and holistic measures as the most effective intervention for cancer-related fatigue.

Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.

Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.

Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients’ quality of life.

Adult and young adult cancer survivors face cognitive and sexual late effects from cancer and its treatment, according to data compiled from an online cancer survivorship care planning tool presented at the 2014 ASCO Annual Meeting.

Patients with locally advanced nasopharyngeal cancer (NPC) do not benefit from the addition of neoadjuvant gemcitabine, carboplatin, and paclitaxel (GCP) to cisplatin chemoradiation.